Citations

Showing 10 of 108104 citations.

Electrically conductive nanocomposite hydrogels embedded with functionalized carbon nanotubes for spinal cord injury
Liu, Xifeng , Kim, Joseph C. , Waletzki, Brian E., Lu, Lichun , Miller, Alan Lee

Mayo Clinic

New Journal of Chemistry | September 18, 2018 | Volume: 42 | Issue: 21 | Pages: 17671-17681

10.1039/c8nj03038c Get It

Electrically conductive hydrogels incorporated with CNTs support PC12 cell growth and differentiation and hold promise for nerve regeneration.
Potential Benefits of Inhaled Nitric Oxide in Pulmonary Hypertension With Hypoplasia in Premature Neonates—Reply
Ellsworth, Kevin, Weaver, Amy L. , Carey, William A., Ellsworth, Kevin R

Mayo Clinic

JAMA Pediatrics | September 18, 2018 | Volume: 172 | Issue: 11 | Pages: 1103

10.1001/jamapediatrics.2018.2895 | PMID 30242326 Get It

B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation
Inohara, Taku , Kim, Sunghee , Pieper, Karen S. , Blanco, Rosalia , Ezekowitz, Michael D. , Kowey, Peter R. , Reiffel, James A. , Mahaffey, Kenneth W. , Singer, Daniel E. , Piccini, Jonathan P. , Steinberg, Benjamin A , Allen, Larry A. , Fonarow, Gregg C. , Gersh, Bernard J. , Naccarelli, Gerald V. , Chan, Paul S. , Freeman, James V. , Steinberg, Benjamin A. , Peterson, Eric D.

Mayo Clinic

Heart | September 18, 2018 | Volume: 105 | Issue: 5 | Pages: 370-377

10.1136/heartjnl-2018-313642 | PMID 30228248 Get It

Objective The association with B-type natriuretic peptide (BNP), disease progression and outcomes in patients with atrial fibrillation (AF) has not been thoroughly investigated. Methods We evaluated the association between BNP levels and outcomes, including AF progression, composite outcome of major adverse cardiovascular or neurological events (MACNE) and major bleeding, via pooled logistic regression and Cox frailty models in Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II registry. AF progression was defined as either paroxysmal becoming persistent or permanent, or persistent becoming permanent at any follow-up. Results Among 13 375 patients with AF, 2797 with BNP values at baseline (median age (IQR), 72.0 (63.0–80.0) years; 43.0% women; median BNP, 238 (102–502) ng/L; 42.3% prior heart failure) were included in the models evaluating the association between BNP levels and MACNE or major bleeding. Of these, 1282 patients with paroxysmal or persistent AF at baseline were analysed in AF progression model. The likelihood of AF progression (adjusted OR, 1.11 for every 100 ng/mL; 95% CI 1.03 to 1.19) and MACNE (adjusted HR, 1.11 for every doubling in BNP values; 95% CI 1.01 to 1.22) increased with BNP concentration, while the elevated BNP values were not associated with increased risks of major bleeding. BNP values improved the risk prediction of AF progression and MACNE when added to conventional risk estimates. Conclusions BNP levels are associated with increased risk of AF progression and cardiovascular outcomes in patients with AF. Further studies are required to assess whether biomarker-based risk stratification improves patient outcomes. Clinical trial registration NCT01701817 .
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
Chapman, Arlene B., Dahl, Neera K. , Harris, Peter C. , Mrug, Michal , Rastogi, Anjay , Watnick, Terry , Torres, Vicente E. , Harris, Peter C , Torres, Vicente E , Dahl, Neera K , Chebib, Fouad T. , Perrone, Ronald D. , Mustafa, Reem A , Yu, Alan S.L.

Mayo Clinic

Journal of the American Society of Nephrology | September 18, 2018 | Volume: 29 | Issue: 10 | Pages: 2458-2470

10.1681/asn.2018060590 | PMID 30228150 Get It

In the past, the treatment of autosomal dominant polycystic kidney disease (ADPKD) has been limited to the management of its symptoms and complications. Recently, the US Food and Drug Administration (FDA) approved tolvaptan as the first drug treatment to slow kidney function decline in adults at risk of rapidly progressing ADPKD. Full prescribing information approved by the FDA provides helpful guidelines but does not address practical questions that are being raised by nephrologists, internists, and general practitioners taking care of patients with ADPKD, and by the patients themselves. In this review, we provide practical guidance and discuss steps that require consideration before and after prescribing tolvaptan to patients with ADPKD to ensure that this treatment is implemented safely and effectively. These steps include confirmation of diagnosis; identification of rapidly progressive disease; implementation of basic renal protective measures; counseling of patients on potential benefits and harms; exclusions to use; education of patients on aquaresis and its expected consequences; initiation, titration, and optimization of tolvaptan treatment; prevention of aquaresis-related complications; evaluation and management of liver enzyme elevations; and monitoring of treatment efficacy. Our recommendations are made on the basis of published evidence and our collective experiences during the randomized, clinical trials and open-label extension studies of tolvaptan in ADPKD.
Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers
Roy, Debarshi , Bhattacharya, Sayantani Sarkar , Jin, Ling, Jung, Deok‐Beom , Kalogera, Eleftheria , Staub, Julie , Wang, Yaxian , X, Wen, Khurana, Ashwani, Chien, Jeremy , Telang, Sucheta , Chesney, Jason , Tapolsky, Gilles , Petras, Dzeja, Shridhar, Viji , Mondal, Susmita, Roy, Debarshi , Sarkar Bhattacharya, Sayantani, Jung, Deokbeom, Xuyang, Wen, Chien, Jeremey , Sarkar Bhattacharya, Sayantani , Mondal, Susmita, Zhang, Song, Xuyang, Wen, Petras, Dzeja

Mayo Clinic

International Journal of Cancer | September 18, 2018 | Volume: 144 | Issue: 1 | Pages: 178-189

10.1002/ijc.31868 | PMID 30226266 Get It

Metabolic alterations are increasingly recognized as important novel anti‐cancer targets. Among several regulators of metabolic alterations, fructose 2,6 bisphosphate (F2,6BP) is a critical glycolytic regulator. Inhibition of the active form of PFKFB3ser461 using a novel inhibitor, PFK158 resulted in reduced glucose uptake, ATP production, lactate release as well as induction of apoptosis in gynecologic cancer cells. Moreover, we found that PFK158 synergizes with carboplatin (CBPt) and paclitaxel (PTX) in the chemoresistant cell lines, C13 and HeyA8MDR but not in their chemosensitive counterparts, OV2008 and HeyA8, respectively. We determined that PFK158‐induced autophagic flux leads to lipophagy resulting in the downregulation of cPLA2, a lipid droplet (LD) associated protein. Immunofluorescence and co‐immunoprecipitation revealed colocalization of p62/SQSTM1 with cPLA2 in HeyA8MDR cells uncovering a novel pathway for the breakdown of LDs promoted by PFK158. Interestingly, treating the cells with the autophagic inhibitor bafilomycin A reversed the PFK158‐mediated synergy and lipophagy in chemoresistant cells. Finally, in a highly metastatic PTX‐resistant in vivo ovarian mouse model, a combination of PFK158 with CBPt significantly reduced tumor weight and ascites and reduced LDs in tumor tissue as seen by immunofluorescence and transmission electron microscopy compared to untreated mice. Since the majority of cancer patients will eventually recur and develop chemoresistance, our results suggest that PFK158 in combination with standard chemotherapy may have a direct clinical role in the treatment of recurrent cancer.
Treatment data and technical process challenges for practical big data efforts in radiation oncology
Mayo, C., Phillips, Mark H., McNutt, TR, Palta, Jatinder , Dekker, André , Miller, Robert C. , Xiao, Ying , Moran, Jean M. , Matuszak, M.M. , Ayan, AS, Prisciandaro, Joann I. , Thor, Maria, Dixit, Niharika , Killoran, Joseph H., Kaleba, Erin O., Kantor, Michael , Kapoor, Rishabh , Kessler, ML, Lawrence, Theodore S. , Mayo, Charles S. , Lawrence, Theodore S , Gabriel, Peter , Popple, Richard A. , Ruan, Dan

Mayo Clinic

Medical Physics | September 18, 2018 | Volume: 45 | Issue: 10 | Pages: No page available

10.1002/mp.13114 | PMID 30226286 Get It

The term Big Data has come to encompass a number of concepts and uses within medicine. This paper lays out the relevance and application of large collections of data in the radiation oncology community. We describe the potential importance and uses in clinical practice. The important concepts are then described and how they have been or could be implemented are discussed. Impediments to progress in the collection and use of sufficient quantities of data are also described. Finally, recommendations for how the community can move forward to achieve the potential of big data in radiation oncology are provided.
Skeletal Muscle Abnormalities and Iron Deficiency in Chronic Heart Failure
Hlavatá, Kateřina, Šedivý, Petr , Dezortová, Monika , Borlaug, Barry A. , Petrák, Jir̆ı́ , Kautzner, Josef , Hájek, Milan , Borlaug, Barry A , Melenovský, Vojtěch

Mayo Clinic

Circulation: Heart Failure | September 18, 2018 | Volume: 11 | Issue: 9 | Pages: No page available

10.1161/circheartfailure.117.004800 | PMID 30354361 Get It

Background: Heart failure (HF) is often associated with iron deficiency (ID). Skeletal muscle abnormalities are common in HF, but the potential role of ID in this phenomenon is unclear. In addition to hemopoiesis, iron is essential for muscle bioenergetics. We examined whether energetic abnormalities in skeletal muscle in HF are affected by ID and if they are responsive to intravenous iron. Methods and Results: Forty-four chronic HF subjects and 25 similar healthy volunteers underwent 31 P magnetic resonance spectroscopy of calf muscle at rest and during exercise (plantar flexions). Results were compared between HF subjects with or without ID. In 13 ID-HF subjects, examinations were repeated 1 month after intravenous ferric carboxymaltose administration (1000 mg). As compared with controls, HF subjects displayed lower resting high-energy phosphate content, lower exercise pH, and slower postexercise PCr recovery. Compared with non-ID HF, ID-HF subjects had lower muscle strength, larger PCr depletion, and more profound intracellular acidosis with exercise, consistent with an earlier metabolic shift to anaerobic glycolysis. The exercise-induced PCr drop strongly correlated with pH change in HF group ( r =−0.71, P <0.001) but not in controls ( r =0.13, P =0.61, interaction: P <0.0001). Short-term iron administration corrected the iron deficit but had no effect on muscle bioenergetics assessed 1 month later. Conclusions: HF patients display skeletal muscle myopathy that is more severe in those with iron deficiency. The presence of ID is associated with greater acidosis with exercise, which may explain early muscle fatigue. Further study is warranted to identify the strategy to restore iron content in skeletal muscle.
Pediatric Laryngeal Expression and Surgical Treatment of IgG4-Related Disease
Jordan, Victoria A. , Hernandez, Loren P. Herrera , Cofer, Shelagh A. , Roby, Brianne Barnett , Herrera Hernandez, Loren P

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | September 18, 2018 | Volume: 144 | Issue: 12 | Pages: 1183

10.1001/jamaoto.2018.2258 | PMID 30242320 Get It

Aging, Cell Senescence, and Chronic Disease
Kirkland, James L. , Tchkonia, Tamara, Tchkonia, Tamar

Mayo Clinic

JAMA | September 18, 2018 | Volume: 320 | Issue: 13 | Pages: 1319

10.1001/jama.2018.12440 | PMID 30242336 Get It

Paraneoplastic Phenomena in a Patient With Locally Destructive and Metastatic Renal Cell Carcinoma
Pimienta, Allen L., Billings, Thomas A., Fish, Robert, Fish, Robert G, Billings, Thomas A., Fish, Robert G.

Mayo Clinic

Journal of Primary Care & Community Health | September 18, 2018 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/2150132718799023 | PMID 30226091 Get It

Renal cell carcinoma (RCC) accounts for approximately 80% of all primary renal neoplasms in United States causing approximately 65 000 new cases of RCC and 14 000 deaths each year. Symptoms of RCC typically include weight loss and night sweats but may also feature paraneoplastic phenomena in advanced stages as well as flank pain, gross hematuria, scrotal varicocele, inferior vena cava pathology, and a palpable abdominal mass. In this article, we present the course of a patient with advanced RCC, from initial presentation through workup and to eventual diagnosis. The case features late-onset symptoms, extensive paraneoplastic phenomena, and significant physical examination findings. We also review the literature available on RCC and critically analyze inefficiencies of the workup retrospectively.